medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2006, Number 1

<< Back Next >>

Rev Mex Patol Clin Med Lab 2006; 53 (1)

Association of 4G/5G polymorphism of PAI-1 gene with lipid profile in patients with rheumatoid arthritis, osteoarthritis and clinical healthy controls

Ruiz-Quezada SL, Vázquez MM, Cárdenas-Meza M, Martín-Márquez BT, Martínez-Bonilla G, Parra-Rojas I, Oregón-RomeroE, Navarro-Hernández RE, Bernard-Medina G, Muñoz-Valle JF

Language: Spanish
References: 26
Page: 21-28
PDF size: 69.29 Kb.


ABSTRACT

The 4G/5G polymorphism of the plasminogen activator inhibitor type 1 (PAI-1) affects the plasmatic concentration of the protein. Besides, in vitro studies demonstrated that triglycerides, very low density lipoproteins-cholesterol (VLDL-c), insulin and glucose increase the gene expression. Objective: To analyze the genetic and allele frequency of the 4G/5G polymorphism of the PAI-1 and its association with the lipid profile in patients with rheumatoid arthritis (RA), osteoarthritis (OA) and clinical healthy controls (HC). Material and methods: Cross-sectional study. The 4G/5G polymorphism of PAI-1, was analyzed for PCR-RFLP’s (polymerase chain reaction- restriction fragment length polymorphisms) using the restriction enzyme Bsl I. The statistical analysis fulfilled with the SPSS 10.0 and Epi Info 2000. Results: The population studied was in Hardy-Weinberg’s balance. The frequency of the genotypes 5G/5G, 4G/5G, 4G/4G in RA was: 44.1%, 52.9% and 2.9%; in OA: 32.2%, 54.8% and 12.9% and in HC: 35.1%, 51.4% and 13.5%, respectively. The HC with genotype 5G/5G presented increase levels of triglycerides, total cholesterol and VLDL-c (p ‹ 0.05). Conclusions: The genotype 5G/5G is associated with increase of triglycerides, total cholesterol and VLDL-c in HC.


REFERENCES

  1. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992; 35 (5): 498-502.

  2. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001; 358: 903-911.

  3. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nature Reviews 2002; 2: 364.

  4. Pope RM. Apoptosis as a therapeutic tool in rheumatoid arthritis. Nature Review 2002; 2: 1.

  5. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke TD, Greenwald R, Hochberg M, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986; 29: 1039-1049.

  6. Ramos-Niembro F. Manual Clínico de Reumatología. México: JGH Editores, 2000; 1-14, 141-154.

  7. Goldring MB. The role of the chondrocyte in osteoarthrits. Arthritis Rheum 2000; 43 (9): 1916-1926.

  8. Sandell LJ, Aigner T. Articular cartilage and changes in arthritis and induction: Cell biology of osteoarthritis. Arthritis Res 2001; 3: 107-113.

  9. Busso N, So A. Urokinase in rheumatoid arthritis: Causal or coincidental? Ann Rheum Dis 1997; 56: 705-706.

  10. van der Laan WH, Slagboom PE, Meulenbelt I, Verheijen JH, Breedveld FC, Huizinga TWJ. A functional polymorphism in the promoter of plasminogen activator inhibitor-1 is associated with joint destruction in RA. Arthritis Rheum 1998; 41 (9) (suppl): S60.

  11. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342: 1792-1801.

  12. Eriksson P, Nilsson L, Karpe F, Hamsten A. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arteroscler Thromb 1998; 18 (1): 20-26.

  13. Ossei-Gerning N, Mansfield MW, Stickland MH, Wilson IJ, Grant PJ. Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography. Arterioscler Thromb Vasc Biol 1997; 17: 33-37.

  14. Lucchesi D, Pucci L, Bandinelli S, Pilo M, Stellini D, Giannarelli R, Del Prato S, Penno G. The PAI-1 promoter 4G/5G polymorphism does not associate with complications in type 2 diabetes. Diabetes 2001; 50 (suppl 2): A177.

  15. Margaglione M, Grandone E, Di Minno G. Relation between PAI-1 gene locus polymorphism and family history of coronary artery disease. Ann Intern Med 1998; 128: 508-509.

  16. Margaglione M, Grandone E, Cappucci G, Colaizzo D, Giuliani N, Vecchione G, d’Addedda M, Di Minno G. An alternative method for PAI-1 promoter polymorphism (4G/5G) typing. Thromb Haemost 1997; 77: 605-606.

  17. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.

  18. Van Doornum S, McGoll G, Wicks IP. Accelerated atherosclerosis. An extraarticular feature of rheumatoid arthritis? Arthritis Rheum 2002; 46: 862-873.

  19. Ross R. Atherosclerosis: An inflammatory disease. N Engl J Med 1999; 340: 115-126.

  20. Park YB, Lee SK, Lee WK et al. Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol 1999; 26: 1701-1704.

  21. Boers M, Nurmohamed MT, Doelman CJA, Lard LR, Verhoeven AC, Voskuyl AE, Huizinga TWJ, Van der Stadt RJ, Dijkmans BAC, Van der Linden S. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62: 842-845.

  22. Tàssies D, Espinosa G, Muñoz-Rodríguez FJ, Freire C, Cervera R, Monteagudo J, Maragall S, Escolar G, Ingelmo M, Ordinas A, Font J, Reverter JC. The 4G/5G polymorphism of the type 1 plasminogen activator inhibitor gene and thrombosis in patients with antiphospholipid syndrome. Arthritis Rheum 2000; 43: 2349-2358.

  23. Hermans PW, Hibberd ML, Booy R, Daramola O, Hazelzet JA, de Groot R, Levin M. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group. Lancet 1999; 354: 556-560.

  24. Nowak-Gottl U, Strater R, Kosch A, von Eckardstein A, Schobess R, Luigs P, Nabel P, Vielhaber H, Kurnik K, Junker R. The plasminogen activator inhibitor (PAI) -1 promoter 4G/4G genotype is not associated with ischemic stroke in a population of German children. Childhood Stroke Study Group. Eur J Haematol 2001; 66: 57-62.

  25. Wang AY, Poon P, Lai FM, Yu L, Choi PC, Lui SF, Li PK. Plasminogen activator inhibitor-1 gene polymorphism 4G/4G genotype and lupus nephritis in Chinese patients. Kidney Int 2001; 59: 1520-1528.

  26. Margaglione M, Cappucci G, Colaizzo D, Giuliani N, Vecchione G, Grandone E, Pennelli O, Di Minno G. The PAI-1 gene locus 4G/5G polymorphism is associated with a family history of coronary artery disease. Arterioscler Thromb Vasc Biol 1998; 18: 152-156.




2020     |     www.medigraphic.com